Bahrain Approves Use of Oral COVID-19 Antiviral, Paxlovid
- Publish date: Monday، 03 January 2022
- Related articles
- Bahrain Approves Booster Shots for Those Aged 12 to 17
- Bahrain Tops Global COVID-19 Recovery Index
- The Updated Bahrain COVID-19 Protocols
The National Health Regulatory Authority (NHRA) in Bahrain on January 1 approved the emergency use of the oral COVID-19 antiviral, Paxlovid, with the medication expected to arrive in January.
فيديو ذات صلة
This browser does not support the video element.
The medication has been authorised for individuals 18 years old and above who suffer from mild to moderate symptoms and are at an increased risk of developing severe COVID-19 that may lead to mortality.
Paxlovid consists of two, co-packaged antiviral medicine (PF-07321332 and Ritonavir) that are designed to stop the virus causing COVID-19 from multiplying in the body and therefore help those infected to overcome the viral infection.
The Kingdom of Bahrain authorises the emergency use of oral COVID-19 antiviral, Paxlovidhttps://t.co/1T4JGEer7s
— Bahrain News Agency (@bna_en) January 1, 2022
The decision follows the evaluation of data provided by the manufacturer Pfizer, carried out by the NHRA's Pharmaceutical Products Regulation Department (PPR).